Plain-English translation of NCT06809400 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Parkinson Disease research guide βPhase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called designed to help treat Parkinson's disease. Researchers want to understand how safe this medication is, how well people tolerate it, and how the body processes it. The study includes both healthy volunteers and people living with Parkinson's disease.
Parkinson's disease affects how the brain controls movement, and current treatments don't work the same way for everyone. This trial explores whether this new treatment approach could offer another option for people managing Parkinson's symptoms.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you're a healthy volunteer, you'll attend visits over about a year, receive a single dose of the medication or placebo, and have blood tests to monitor how your body handles it. If you have Parkinson's disease, you'll participate for up to 18 months, receive multiple doses of the medication or placebo over time, and have regular visits with blood work and cognitive assessments to track safety and how the treatment affects your symptoms.
AI-generated summary from trial data Β· Jun 25, 2026 Β· Not medical advice
United States